Biosysen Limited (stock code: 01355) reported a substantial expansion in its share base for the month ended 30 September 2026, according to its latest filing with Hong Kong Exchanges and Clearing Limited.

The company’s issued ordinary shares (excluding treasury shares) climbed by 596.53 million during the month to 1.79 billion, representing a 50.00% increase from the August closing level of 1.19 billion. No treasury shares were outstanding before or after the period.

Authorised capital remained unchanged at 10.00 billion ordinary shares with a par value of HKD 0.01 each, equivalent to HKD 100.00 million.

Biosysen confirmed that its public float comfortably met the Main Board’s minimum 25% threshold as at 30 September 2026.

The filing also reconfirmed the existence of HK$50.00 million zero-coupon unsecured redeemable convertible bonds due 2031, carrying a conversion price of HKD 0.129 per share. No conversions or treasury-share transfers under these bonds were recorded during September; the instrument therefore retains the capacity to create up to 50.00 million additional ordinary shares if fully converted.

No movements were reported under share option schemes, warrants, or other equity-linked arrangements, and the company indicated full compliance with all regulatory and corporate authorisation requirements for the month.